AC Immune (ACIU) Income from Continuing Operations (2015 - 2026)
AC Immune (ACIU) reported Income from Continuing Operations of 18900946.3 for Q1 2026, up 10.7% year-over-year from 17074453.71 in Q1 2025, and down 5.1% on a QoQ basis from 17983063.42 in Q4 2025.
AC Immune (ACIU) has 12 years of Income from Continuing Operations data on file, last reported at 18900946.3 in Q1 2026.
- Quarterly Income from Continuing Operations rose 10.7% year-over-year to 18900946.3 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 82302232.45 (down 41.87% YoY) and the FY2025 annual result came in at 84968134.06, down 46.21% from the prior year.
- Income from Continuing Operations declined to 18900946.3 in Q1 2026 per ACIU's latest filing, from 17983063.42 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 6351602.46 in Q3 2024 and bottomed at 25593986.06 in Q2 2025.
- The 5-year median for Income from Continuing Operations is 18927913.25 (2023), against an average of 17360965.7.
- The widest annual swing landed in 2024, when Income from Continuing Operations jumped 137.06%; it then sank 412.11% in 2025.
- Tracing ACIU's Income from Continuing Operations over 5 years: stood at 19457720.74 in 2022, then jumped by 72.53% to 5345914.91 in 2023, then tumbled by 237.25% to 18029196.07 in 2024, then advanced by 0.26% to 17983063.42 in 2025, then decreased by 5.1% to 18900946.3 in 2026.
- Per Business Quant, the three latest ACIU Income from Continuing Operations figures stand at 18900946.3 (Q1 2026), 17983063.42 (Q4 2025), and 19824236.68 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | AC Immune | 325.88 Mn | 211.53 Mn | - | -18.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -18.90 Mn |
| Dec 31, 2025 | -17.98 Mn |
| Sep 30, 2025 | -19.82 Mn |
| Jun 30, 2025 | -25.59 Mn |
| Mar 31, 2025 | -21.17 Mn |
| Dec 31, 2024 | -18.03 Mn |
| Sep 30, 2024 | 6.35 Mn |
| Jun 30, 2024 | -25.17 Mn |
| Mar 31, 2024 | -20.46 Mn |
| Dec 31, 2023 | -5.35 Mn |
| Sep 30, 2023 | -17.14 Mn |
| Jun 30, 2023 | -18.71 Mn |
| Mar 31, 2023 | -18.93 Mn |
| Dec 31, 2022 | -19.46 Mn |
| Sep 30, 2022 | -13.99 Mn |
| Jun 30, 2022 | -20.39 Mn |
| Mar 31, 2022 | -20.40 Mn |
| Dec 31, 2021 | -23.07 Mn |
| Sep 30, 2021 | -17.34 Mn |
| Jun 30, 2021 | -20.91 Mn |
| Mar 31, 2021 | -18.51 Mn |
| Dec 31, 2020 | -21.57 Mn |
| Sep 30, 2020 | -20.63 Mn |
| Jun 30, 2020 | -16.33 Mn |
| Mar 31, 2020 | -7.95 Mn |
| Dec 31, 2019 | -19.65 Mn |
| Sep 30, 2019 | 18.49 Mn |
| Jun 30, 2019 | -16.85 Mn |
| Mar 31, 2019 | 63.83 Mn |
| Dec 31, 2018 | -14.75 Mn |
| Sep 30, 2018 | -13.74 Mn |
| Jun 30, 2018 | -11.32 Mn |
| Mar 31, 2018 | -12.25 Mn |
| Dec 31, 2017 | 4.22 Mn |
| Sep 30, 2017 | -9.14 Mn |
| Jun 30, 2017 | -12.51 Mn |
| Mar 31, 2017 | -9.42 Mn |
| Dec 31, 2016 | -4.77 Mn |
| Sep 30, 2016 | -9.33 Mn |
| Mar 31, 2016 | -6.22 Mn |
| Dec 31, 2015 | -5.64 Mn |
| Sep 30, 2015 | 20.86 Mn |